Overview | Index | Requesting Use of Contract Resources | DAIDS Home

Currently Funded Resources

The following resources are available to investigators seeking assistance in drug discovery and basic research:

• Databases

  Computerized databases linking chemical structures with antiviral and antimicrobial efficacy data are maintained to assist in tracking compounds for further study. DAIDS staff can search these databases upon request and provide investigators nonproprietary information regarding specific compounds to help guide their drug development efforts.

• In Vitro Efficacy Evaluations

  Agents with therapeutic potential in the following areas can be evaluated by DAIDS-sponsored contractors for in vitro efficacy:
  

  • HIV Therapeutics
  • OI Therapeutics
  • TB Therapeutics
  • Topical Microbicides
  
  
• In Vitro Immunologic Evaluations

  Potential therapies can be evaluated for effects on immunological parameters in uninfected or HIV-infected human cells and in cells isolated from drug-treated animals. Capabilities include determination of effects on immune cell proliferation, differentiation, and cytotoxic function; evaluation of virus neutralization by antibodies; and assessment of cytokine modulation by the proposed therapies.

• NIH AIDS Research and Reference Reagent Program

  Over 1000 biological and chemical reagents potentially useful to the AIDS research community can be obtained via this program. Information about this program and a searchable catalog of reagents is available via this link.

Grant Mechanisms

The following describes grant-based funding opportunities for investigators in the areas of drug discovery and basic research:

• The NIH Grants and Contracts home page provides links to general information regarding NIH and SBIR/STTR grant mechanisms and to the NIH Guide for Grants and Contracts.

• The NIAID Council News - Extramural Information Center home page provides links to specific programs sponsored by The National Institute of Allergy and Infectious Diseases to which investigators can submit applications.

• The National Cooperative Drug Discovery Group for Opportunistic Infections (NCDDG-OI) grant program supports consortia of academia, industry, and government investigators working collaboratively on targeted discovery and preclinical development of new OI drugs and therapeutic strategies.

  Please contact Dr. Barbara Laughon (phone: 301-402-2304; email: blaughon@niaid.nih.gov for additional information regarding the NCDDG-OI program.

• The Novel HIV Therapies: Integrated Preclinical/Clinical Program (IPCP) supports (1) the discovery and preclinical development of new anti-HIV drugs and therapeutic concepts; and (2) the translation of innovative preclinical findings to the clinic via small clinical studies. This grant program funds consortia of investigators from academia and the private sector, working collaboratively on the development of a defined therapeutic concept identified and proposed by the collaborative group. This mechanism is particularly appropriate for highly experimental therapeutic strategies that are new or otherwise not yet ready for large clinical trials.

  Please contact Dr. Sandra Bridges (phone: 301-496-8197; email: sbridges@niaid.nih.gov for additional information regarding the IPCP.